<?xml version="1.0" encoding="UTF-8"?>
<ref id="B145-ijms-21-05559">
 <label>145.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Chen</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Xu</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Zeng</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Qian</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Wei</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Yang</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Shen</surname>
    <given-names>Q.</given-names>
   </name>
   <name>
    <surname>Gong</surname>
    <given-names>Z.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications</article-title>
  <source>Front. Oncol.</source>
  <year>2019</year>
  <volume>9</volume>
  <fpage>852</fpage>
  <pub-id pub-id-type="doi">10.3389/fonc.2019.00852</pub-id>
  <pub-id pub-id-type="pmid">31552177</pub-id>
 </element-citation>
</ref>
